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Summary
Background: The DNA damage checkpoint is a protein
kinase-based signaling system that detects and signals
physical alterations in DNA. Despite having identified
many components of this signaling cascade, the exact
mechanisms by which checkpoint kinases are acti-
vated after DNA damage, as well as the role of the
checkpoint mediators, remain poorly understood.
Results: To elucidate the mechanisms that underlie the
MEC1 and RAD9-dependent activation of Rad53, the
Saccharomyces cerevisiae ortholog of Chk2, we mapped
and characterized in vivo phosphorylation sites present
on Rad53 after DNA damage by mass spectrometry. We
find that Rad53 requires for its activation multisite
phosphorylation on a number of typical and atypi-
cal Mec1 phosphorylation sites, thus confirming that
Rad53 is a direct target of Mec1, the mammalian ATR
homolog. Moreover, by using biochemical reconstitu-
tion experiments, we demonstrate that efficient and di-
rect phosphorylation of Rad53 by Mec1 is only ob-
served in the presence of purified Rad9, the archetypal
checkpoint mediator. We find that the stimulatory activ-
ity of Rad9 requires a phospho- and FHA-dependent
interaction with Rad53, which allows Rad53 to be rec-
ognized as a substrate for Mec1.
Conclusions: Our results indicate that Rad9 acts as a
bona fide signaling adaptor that enables Rad53 phos-
phorylation by Mec1. Given the high degree of conser-
vation of checkpoint signaling in eukaryotes, we pro-
pose that one of the critical functions of checkpoint
mediators such as MDC1, 53BP1, or Brca1 is to act as
PIKK adaptors during the DNA damage response.
Introduction
The DNA damage checkpoint is a signal transduction
system that detects and signals physical alterations in*Correspondence: durocher@mshri.on.caDNA as well as monitoring the integrity of replication
forks [1]. When this highly conserved genome surveil-
lance mechanism is disrupted, cells become sensitive
to DNA damaging agents and DNA replication inhibitors
and accumulate genetic lesions at high rates [2]. In hu-
man cells, disruption of components of the DNA dam-
age checkpoint, such as ATM, Chk2 and p53, is asso-
ciated with an aberrant response to DNA damage,
resulting in genome instability and heightened predis-
position to cancer [3].
In the budding yeast Saccharomyces cerevisiae, the
DNA damage checkpoint is in large part under the con-
trol of the PI(3) kinase-like kinase (PIKK) Mec1, the or-
tholog of the ATR Ser/Thr protein kinase [4, 5]. In com-
plex with its interacting protein Ddc2, Mec1 has been
proposed to detect processed DNA lesions via an in-
teraction with RPA-coated single-stranded DNA [6].
Upon Mec1 activation, the tandem BRCT domain-con-
taining protein Rad9 becomes highly phosphorylated
on putative Mec1 consensus sites characterized by
Ser/Thr-Gln (S/T-Q) motifs [7]. Rad9 phosphorylation
triggers the binding of Rad53, the Chk2 ortholog, to
Rad9 in a manner that depends on both the N-terminal
(FHA1) and C-terminal (FHA2) FHA domains of Rad53
[7–11]. Rad9 is essential for DNA damage signaling in
the G1 and G2/M phases of the cell cycle, whereas in
S phase, its function in the replication checkpoint is
dispensable and appears to be substituted by Mrc1, a
replication fork-associated protein [12, 13].
In vertebrates, there is no single Rad9 ortholog read-
ily identifiable, but rather a family of tandem BRCT do-
main-containing proteins that act in the checkpoint re-
sponse. These Rad9 homologs are Brca1, 53BP1, and
MDC1 and are commonly referred to as checkpoint me-
diators [14]. Like Rad9, human checkpoint mediators
localize directly to sites of DNA damage, are often sub-
strates of PIKKs, and are required for the downstream
propagation of the DNA damage signal [15–17]. The
shared properties between the budding yeast Rad9 and
human checkpoint mediators suggest that a common
underlying role in the checkpoint response may govern
checkpoint mediator action.
Two main models attempt to explain the requirement
for checkpoint mediators in Chk2-like kinase activation.
The first model, based on a study by Gilbert et al. [18],
proposes that Rad9 activates Rad53 in a manner akin
to a solid-state catalyst by increasing the local Rad53
concentration. The resulting increase in Rad53 concen-
tration is thought to be sufficient to trigger trans auto-
phosphorylation and catalytic activation. This model
(called herein the “solid-state catalyst” model) was in-
ferred from hydrodynamic data of the Rad9 complex
and on the observation that recombinant Rad53 pro-
duced from Escherichia coli is extensively phosphory-
lated and active. However, the solid-state catalyst
model of Rad53 activation does not satisfyingly ac-
count for the observation that Rad53 is phosphorylated
in response to DNA damage independently of its kinase
activity ([19–21] and below) or that covalent linking of
Rad53 to Ddc2 partially alleviates the requirement of
Rad9 for Rad53 activation [22]. A second model has
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checkpoint mediators) are critical for the PIKK-depen-
dent phosphorylation of Chk2-like kinases in response
to DNA damage. This second model suggests that the
main role of Rad9 is to act as a protein that recruits
Rad53 to Mec1. In this model, Rad9 acts as a bona fide
signaling adaptor, which can be defined as a protein
lacking known catalytic domains that physically link at
least two other proteins to facilitate a signaling event
[23]. However, direct biochemical evidence to support
the adaptor model has remained elusive.
In this study, we investigated how Rad53 phosphory-
lation influenced its catalytic activation. By using mass
spectrometry coupled to metal-affinity enrichment of
phosphopeptides, we mapped unambiguously phos-
phorylation sites on Rad53 purified from cells sub-
jected to DNA damage. Results from the mutational
analysis of these sites are consistent with a model
whereby PIKKs play a direct and essential role in con-
verting a catalytically latent Rad53 enzyme to an active
state by phosphorylating multiple sites on Rad53. Fur-
thermore, we have tested the adaptor model in bio-
chemical reconstitution assays by using purified Mec1,
Rad53, and Rad9, and our results indicate that Rad9
acts as a signaling adaptor necessary for efficient
Rad53 phosphorylation by Mec1. Because MDC1, Brca1,
and 53BP1 are analogous to Rad9 in many respects
and are required for multiple PIKK phosphorylation
events, our work supports a model whereby BRCT do-
main-containing checkpoint mediators act as PIKK
phosphorylation adaptors to ensure the proper spatio-
temporal regulation of the DNA damage response.
Results
In this study, we examined the contribution of the
Rad53 FHA domains to the regulation of Rad53 kinase
activation in response to DNA damage. We mutated a
critical Arg residue in each of the Rad53 FHA domains
to Ala (R70A in FHA1 and R605A in FHA2; Figure 1A) in
order to impair the phosphopeptide binding activity of
the mutated FHA domain [11, 24]. These mutations
were generated alone or in combination to yield the
rad53FHA1, rad53FHA2, or rad53FHA1,2 alleles. We also
generated a kinase-dead allele of RAD53, rad53D339A
[25]. Each plasmid-borne allele (including the wild-type
[wt] allele) was introduced in a rad53 sml1 strain
(SML1 mutation is required to maintain the viability of
the RAD53 deletion; [26]). DNA damage-induced Rad53
activity was elicited by addition of the UV-mimetic drug
4-nitroquinoline oxide (4-NQO), and Rad53 activity in
the resulting strains was monitored by in situ kinase
assays (ISA; [19], or by examining protein gel mobility
shifts due to phosphorylation). As shown in Figure 1B,
we observe that Rad53 catalytic activation absolutely
requires at least one functional FHA domain, an obser-
vation also corroborated by others [8, 27]. This result
indicates that FHA-dependent binding of Rad53 to up-
stream activators is required for its conversion from a
latent state to an active one.
We also noticed that in stark contrast to the lack of
a DNA damage-induced mobility shift displayed by
Rad53 in the rad53FHA1,2 strain (Figure 1B, lane 10, bot-
tom), Rad53D339A displays a noticeable mobility shift af-Figure 1. Rad53 Is Modified in Two Distinct Phosphorylation Events
(A) Domain architecture of Rad53 showing the two FHA domains
(FHA1 and FHA2) flanking the central catalytic protein kinase do-
main. Also indicated are the sites of mutations abolishing phospho-
peptide binding activity in the FHA1 (R70A) or FHA2 (R605A) do-
mains. The site of the D339A mutation in the Rad53 kinase domain,
which abolishes kinase activity, is also indicated.
(B) Analysis of Rad53 activity and phosphorylation after DNA dam-
age. Strains harboring the indicated RAD53 alleles were (+) or were
not (−) treated with the UV-mimetic drug 4-NQO. Whole-cell ex-
tracts (WCE) were prepared by glass bead lysis in TCA, and pro-
teins were separated by SDS-PAGE. Rad53 activity was measured
by in situ kinase assays ([ISA], top), and Rad53 phosphorylation
was estimated by examining gel mobility shifts after immunoblot
analysis (bottom).
(C) Rad53 kinase-independent phosphorylation depends on Rad9.
rad53D339A cells containing either the RAD9, rad9D, or rad99TA al-
leles (the rad99TA allele contains T/A mutations on nine TQ motifs)
were arrested in G1 by exposure to α factor and then treated with
4-NQO. Phosphorylation of Rad53 was examined by immunoblot
as described above. Rad53D339A phosphorylation is dependent on
the PIKK phosphorylation sites on Rad9.ter DNA damage, albeit not at the level seen with the
wild-type allele (Figure 1B, lane 4, bottom). This mobil-
ity shift, also observed in [21], is abrogated by treat-
ment with λ protein phosphatase (data not shown), indi-
cating that the mobility shift is due to a phosphorylation
event independent of Rad53 catalytic activity but which
requires the phosphothreonine binding activity of the
FHA domains. Because both Rad53 FHA domains are
required for optimal binding to Rad9 ([8] and data not
shown), we next examined whether the Rad53 kinase-
independent phosphorylation event requires Rad9 resi-
dues necessary for its interaction with Rad53. Thus,
the kinase-dead rad53D339A allele was introduced in a
RAD9+ strain, a strain lacking RAD9 (rad9), or in a
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srequired for the phosphorylation-dependent Rad53-
aRad9 interaction [7]. As shown in Figure 1C, the DNA
edamage-induced phosphorylation of the Rad53D339A
tprotein in G1 (a cell cycle phase where Rad53 activa-
vtion is totally dependent on RAD9) is totally abolished
tin the rad99TA strain, indicating that this Rad53 kinase-
oindependent phosphorylation event is entirely depen-
fdent on a functional Rad9-Rad53 interaction. Further-
mmore, as described in the Supplemental Data available
iwith this article online, this phosphorylation step is de-
ppendent on Mec1 and generates phospho-S/T-Q epi-
Ftopes, suggesting that Mec1 may be the protein kinase
nresponsible for this phosphorylation event (Figure S1).
o
SMapping of Rad53 Phosphorylation Sites In Vivo
pUsing Mass Spectrometry
lBecause phosphorylation of Rad53D339A after DNA dam-
page is dependent on the same genetic determinants re-
rquired for Rad53 activation, we hypothesize that the
btrans-phosphorylation event observed participates in
tRad53 catalytic activation. We therefore sought to iden-
ctify the phosphorylation sites involved in this event in
forder to characterize their function. As outlined in Fig-
fure 2A, our strategy was to map phosphorylation sites
on Rad53D339A in order to identify sites that are inde-
Mpendent of Rad53 kinase activity. In parallel, we also
fmapped sites on wt Rad53 after DNA damage in order
Wto deduce which sites are likely to represent autophos-
kphorylation events. Therefore, to map Rad53 phosphory-
mlation sites in vivo, we introduced FLAG epitope-tagged
tRAD53 or rad53D339A alleles under the control of the
yinducible GAL1/10 promoter into a rad53D sml1 strain
Rto facilitate purification. The C-terminal FLAG epitope
sdoes not alter Rad53 function as the RAD53-FLAG
wplasmid restores tolerance to DNA damage when in-
a
troduced in a rad53D strain (Figure S2). Rad53-FLAG
m
and Rad53D339A-FLAG were both immunopurified from
t
4-NQO-treated, asynchronously dividing cells to iden- m
tify phosphorylation sites that are dependent or inde- o
pendent of Rad53 catalytic activity according to the 3
scheme described in Figure 2B. S
After immunopurification (Figure 2C), Rad53-FLAG or r
Rad53D339A-FLAG was digested with trypsin or a com- D
bination of trypsin-Glu-C or trypsin-chymotrypsin pro- p
teases. The resulting peptides were split in two aliquots.
One aliquot was analyzed by tandem mass spectrome- c
try to estimate protein coverage. Our analysis indicates c
that we obtained peptide coverage of 74.7% of the total t
protein sequence (data not shown). The other aliquot e
was enriched for phosphopeptides by passing the pep- o
tide mixture over a Fe (III)-IMAC column, and phosphor- o
ylation sites were identified by tandem mass spectrom- b
etry [28]. By using this method, we unambiguously (
detected 42 phosphorylated peptides (Tables S1–S3) w
representing 14 sites on the Rad53D339A sample (Figure t
2E). In addition to identifying phosphopeptides corre- o
sponding to most of the sites found on the Rad53D339A R
sample (boxed residues, Figure 2E), we identified 13 n
additional sites on the wild-type protein (Figure 2E). o
Analysis of the phosphorylation sites mapped on t
Rad53D339A reveals that five of the 14 sites mapped s
tconform to the S/T-Q consensus for PIKK phosphoryla-ion (Table S1). However, we also noted four additional
ites that contain a hydrophobic residue immediately
fter the phosphoacceptor residues (S/T-ψ; where ψ is
ither Ala, Val, Ile, Leu, Phe, or Trp residues), a motif
hat is found phosphorylated by PIKKs in vitro and in
ivo (see [29]). Of the remaining five sites, one appears
o be a proline-directed site (S375), perhaps indicative
f Cdk-dependent phosphorylation. As for the 13 sites
ound solely in the Rad53 wt sample, we predict that
ost correspond to autophosphorylation sites. Satisfy-
ngly, two of the 13 sites (S350 and T354) map to the
redicted activation segment of Rad53 (Table S1 and
igures 2D and 2E), a functionally relevant motif in ki-
ases that is often phosphorylated. In addition, many
f the phosphorylation sites are found as clusters (e.g.,
745, S746, S748, and S750). Whether Rad53 acts as a
rocessive kinase and prefers previously phosphory-
ated substrates or whether the observed clusters of
hosphorylation sites represent particularly accessible
egions of the protein is unknown due to the paucity of
ona fide Rad53 substrates. Lastly, from the analysis of
hese 13 sites, we could not detect any obvious Rad53
onsensus phosphorylation site or any site that con-
orms to the Rad53 phosphorylation consensus derived
rom the analysis of Swi6 phosphorylation [30].
ultisite Phosphorylation Is Required
or Rad53 Function
e next turned our attention to the sites mapped on
inase-dead Rad53D339A after DNA damage, as they
ay represent sites that directly participate in Rad53
ransactivation. To determine whether these phosphor-
lation sites play a critical role in catalytic activation of
ad53, we mutated each of the 14 phosphorylation
ites individually or in pairs. Rad53 catalytic activity
as then evaluated by ISA, mobility shift on SDS-PAGE,
nd by examining the ability of the phosphorylation site
utants to complement the DNA damage sensitivity of
he rad53D sml1 strain. None of the single or double site
utants displayed sensitivity to DNA damage or loss
f catalytic activity, as measured by ISA (Figures 3A and
B and data not shown). However, mutation of residues
485/489 (Rad53A1) and S560/563 (Rad53A5) leads to a
eproducible reduction in Rad53 mobility shift after
NA damage, suggesting that these sites are indeed
hosphorylated in vivo (Figure 3B, bottom).
Next, we considered the possibility that multiple sites
ontribute to Rad53 kinase activation. Therefore, we
ombined phosphorylation site mutations and analyzed
heir phenotypes, as described above. To our surprise,
ven though we could nearly abolish the mobility shift
f Rad53 after DNA damage when we mutated a total
f six sites (Rad53A6 mutant), its activity as measured
y ISA (Figure 3B, top) and DNA damage sensitivity
Figure 3C) remained similar to wt levels. However,
hen we mutated additional residues resulting in muta-
ions of eight or nine of the 14 sites (e.g., the Rad53A8
r Rad53A9 mutants), we reached a critical point where
ad53 cannot be converted into an active protein ki-
ase after exposure to DNA damaging agents, as dem-
nstrated by the lack of activity in the ISA (Figure 3B,
op) and DNA damage sensitivity (Figure 3C). These re-
ults suggest that Rad53 activation is dependent on
he contribution of multiple phosphorylated residues.
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(A and B) Strategy for the identification Rad53 phosphorylation sites by mass spectrometry. Rad53 phosphoregulation occurs in two distinct
steps. (A) The Rad53D339A kinase-dead variant was used to identify sites that are phosphorylated independently of Rad53 catalytic activity.
Conversely, sites that are present only on wild-type (wt) Rad53 are likely to represent autophosphorylation sites. (B) After immunopurification
of Rad53, the purified protein was digested by a combination of proteases and the sample was subjected either to tandem mass spectrometry
to estimate coverage or to Fe(III)-IMAC chromatography to enrich for phosphorylated peptides that were subsequently identified by mass
spectrometry.
(C) Immunopurification of Rad53 proteins. Equal fractions of crude cell lysates, proteins bound to anti-FLAG beads, and proteins eluted from
the beads were stained with colloidal Coomassie. The eluate fraction corresponds to 5% of the total quantity of protein used for phosphoryla-
tion site mapping by mass spectrometry.
(D) Typical MS/MS spectrum obtained from phospho-Rad53 showing a fragmentation pattern identifying doubly phosphorylated Ser350 and
phosphorylated Thr354 residues in the activation segment of Rad53. Please refer to Tables S1–S3 for a complete list of the peptide sequences
and the position of the phosphorylation sites.
(E) In vivo phosphorylation sites identified by mass spectrometry from the Rad53D339A sample (sites above the drawn Rad53 molecule) and
wt Rad53 (sites below). Boxed residues represent sites that we also found in the wt Rad53 sample. Sequences of the sites are found in Table
S1; full sequences of the corresponding peptides in which these sites were identified can be found in Table S3.
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(A) Series A mutations.
(B) Strains harboring the indicated RAD53 alleles were (+) or were not (−) treated with 3 M 4-NQO. WCE were prepared and proteins
separated by SDS-PAGE. Rad53 activity was monitored by ISA (top), and Rad53 phosphorylation was estimated by gel mobility shift after
immunobloting (bottom). Combinations of eight or nine mutations lead to a defect in Rad53 activation (mutants Rad53A8 and Rad53A9).
However, note that some combinations of mutants affect Rad53 mobility shift after DNA damage without affecting its kinase activity.
(C) Strains containing the alleles described above were diluted serially 10-fold and spotted on agar plates containing 4-NQO at the indi-
cated concentrations.
(D) Bacterially produced Rad53A8 has protein kinase activity. His-tagged Rad53 and Rad53A8 were expressed and purified in E. coli as
described in the Supplemental Experimental Procedures. Note that Rad53A8 displays an extensive mobility shift comparable to wt Rad53,
indicating that it has protein kinase activity.The Rad53A8 and Rad53A9 mutants are expressed at t
pwt or near wt levels in yeast cells and interact with
Rad9 (data not shown). These observations rule out the R
bpossibility that the defect in Rad53 activity is simply
due to loss of protein expression or loss of interaction i
owith Rad9. Importantly, expression of Rad53A8 in bacte-
ria results in an active protein kinase as demonstrated i
mby the substantial autophosphorylation observed on
Rad53A8 (Figure 3D). This latter result indicates that the d
Mrad53A8 allele is likely to be inactive in yeast due to
the disruption of regulatory residues rather than protein
wmisfolding. Based on the above results, we conclude
that MEC1-dependent Rad53 trans phosphorylation is t
prequired to convert the latent Rad53 enzyme into an
active protein kinase. p
t
kRad9 Stimulates Mec1 Phosphorylation
of Rad53 In Vitro w
RThe observation that putative Mec1 phosphorylation
sites are required for Rad53 activation in vivo suggests M
Ra role for Mec1 in Rad53 activation that is upstream ofhe solid-state catalyst model. In this model, Rad9 is
roposed to catalyze in trans autophosphorylation of
ad53 in soluble Rad9-Rad53 complexes that have
een released from the lesion at which the Mec1 kinase
s tethered [18, 31]. However, considering our new data
n the phosphoregulation of Rad53, we reasoned that
nstead of acting solely as a solid-state catalyst, Rad9
ay also be acting to recruit Rad53 to sites of DNA
amage to allow it to be efficiently phosphorylated by
ec1.
To directly test the adaptor model, we first examined
hether Mec1 can phosphorylate Rad53 directly in vi-
ro. To do so, we optimized a purification procedure to
roduce full-length, recombinant Rad9 from yeast and
erformed large-scale immunoprecipitations of FLAG-
agged Mec1 and kinase-dead Mec1 proteins (Mec1-
d, Figures 4A and 4B). With these purified proteins,
e examined the capacity of Mec1 to phosphorylate
ad53D339A directly in vitro. We incubated purified
ec1 with increasing amounts of bacterially produced
ad53D339A or the model PIKK substrate PHAS-I [32].
Rad9 as a Phospho-Dependent Mec1 Adaptor
1369The protein kinase reactions were carried out in the
presence of radiolabeled ATP, and phosphorylation was
detected and quantitated by phosphorimaging. At equi-
molar concentrations, Rad53 is consistently phosphor-
ylated less than PHAS-I (Figures 4C and 4D) even
though there is only one PIKK site, S111, on PHAS-I
[5] compared to 14 potential phosphoacceptor sites onFigure 4. Direct Phosphorylation of Rad53 by Mec1
(A and B) Purified recombinant proteins used in the in vitro phosphorylation assays of this study. Full-length GST-TEV-Rad9 (A) was purified
from yeast cells by a three-step chromatography protocol that included heparin-sulfate chromatography as a first purification step (F1). The
Rad9-containing eluate was then bound to glutathione-Sepharose beads and, finally, Rad9 was released after TEV protease cleavage of the
fusion protein (F3). Full-length FLAG-His10-Mec1 or FLAG-His10-Mec1-kd (B) was purified from yeast cells by using Ni2+-NTA-agarose affinity
columns followed by FLAG immunopurification. The residue mutated in the kinase-dead mec1-kd allele is D2224A [50].
(C) Rad53 is a poor Mec1 substrate relative to PHAS-I. In vitro Mec1 kinase assays using equimolar concentrations of Rad53D339A or PHAS-I as
substrates were performed in the presence of [γ-32P]ATP. Proteins were separated by SDS-PAGE and transferred onto a PVDF membrane,
and radioactivity incorporation was measured by phosphorimaging (top). The presence of Rad53 and PHAS-I was monitored by immunoblot-
ting using anti-His tag and anti-PHAS-I antibodies, respectively (bottom panels).
(D) Phosphorimager quantification of the in vitro kinase assays performed in (B). Note that at equimolar concentrations, Rad53 is markedly
less efficiently phosphorylated than PHAS-I.
(E) Kinase reactions as described in (B) using 2 M of the indicated substrates were carried out by using either wt Mec1 or Mec1-kd. The
presence of substrate was monitored by immunoblotting using an anti-His tag antibody which recognizes either substrates (bottom panels).Rad53 (i.e., all sites mapped on Rad53D339A). The ob-
servation that Rad53 behaves as a poor Mec1 sub-
strate relative to the nonphysiological PIKK substrate
PHAS-I is clearly at odds with the quantitative phos-
phorylation of Rad53 observed in vivo (Figure 1). As a
control, we ensured that the phosphorylation of both
Rad53 and PHAS-I is dependent on Mec1 kinase activ-
Current Biology
1370ity by carrying out kinase assays with the Mec1-kd pro- R
tein instead of wt Mec1. As expected, Mec1-kd is m
unable to support efficient phosphorylation of either p
PHAS-I or Rad53 (Figure 4E, lanes 5 and 8). R
In vivo, Rad53 is efficiently phosphorylated in a i
RAD9-dependent manner and in a Rad53 FHA domain-
dependent manner (Figure 1). Therefore, the observa- I
tion that Rad53 is a relatively poor Mec1 substrate w
prompted us to test whether Rad9 can stimulate phos- T
phorylation of Rad53D339A by Mec1. Kinase assays R
were performed with fixed amounts of Rad53D339A and p
Mec1 and increasing amounts of Rad9. Under these t
conditions, Rad9 is clearly able to stimulate Rad53 t
phosphorylation in a dose-dependent manner (Figure F
5A). Intriguingly, we observe that Rad9 does not appear w
to incorporate as much 32P as Rad53 in these assays. 3
This observation can be reconciled with our finding that r
Rad9 purified from yeast cells is substantially phos- R
phorylated on multiple sites, including at some S/T-Q a
residues (Figure S3), a condition that may preclude ad- c
ditional Mec1 phosphorylation. Nevertheless, the stim- g
ulation of Rad53 phosphorylation is not due to contami- t
nating kinase activity in the Rad9 preparation because:
(1) omission of Mec1 does not lead to appreciable p
Rad53 phosphorylation (Figure 5A); (2) Rad53 phos- p
phorylation is not observed when Mec1-kd is used in- t
stead of wt Mec1 (Figure 5B); and (3) Rad53 phosphory- d
lation by Mec1 is inhibited by the PIKK inhibitor t
wortmannin (Figure 5D). We therefore conclude that v
Rad9 facilitates Rad53 phosphorylation by Mec1 in c
vitro. t
Two possible models can explain the observed effect m
of Rad9 on Rad53 phosphorylation by Mec1. Firstly, m
Rad9 may directly stimulate Mec1 catalytic activity. If S
this is the case, one would expect that phosphorylation w
of other substrates such as PHAS-I may also be stim- T
ulated by Rad9. Secondly, Rad9 may act as an adaptor a
(or scaffold) to bring Rad53 in close proximity to Mec1. s
To test the first model, we examined the effect of Rad9 t
on the phosphorylation of PHAS-I by Mec1. As shown m
in Figures 5B and 5C, addition of Rad9 does not lead
p
to appreciable stimulation of PHAS-I phosphorylation,
t
indicating that Rad9 does not act by increasing Mec1
scatalytic activity.
Next, we examined whether Rad9 stimulation of
DRad53 phosphorylation in vitro depends on the same
determinants for Rad53 activation in vivo, namely a
Rrequirement for functional Rad53 FHA domains and
bRad9 phosphorylation. First, we employed the kinase
Aassay described above but in some reactions sub-
mstituted Rad53D339A with a mutant version of this pro-
Rtein incorporating the R70A and R650A mutations,
dwhich disable the Rad53-Rad9 interaction in vivo
t(Rad53D339A, FHA1,2). As shown in Figure 5D (lane 8), the
qRad9 stimulation of Rad53 phosphorylation clearly re-
oquires the Rad53-Rad9 phospho-dependent interac-
stion, as mutation of the Rad53 FHA domains completely
tabrogates the effect of addition of Rad9. Secondly, we
sexamined whether dephosphorylation of Rad9 (Figures
RS3B and S3C) prior to kinase assays affects its ability
nto stimulate phosphorylation of Rad53 by Mec1. As
tshown in Figure 5E, phosphorylation of Rad9 is essen-
atial for its ability to stimulate Rad53 phosphorylation
by Mec1. We therefore conclude that Rad9 stimulates ead53 phosphorylation by Mec1 in vitro via an FHA do-
ain-dependent interaction between Rad53 and phos-
ho-Rad9, thus recapitulating the requirement for the
ad9-Rad53 interaction essential for Rad53 activation
n vivo.
n Vitro Rad53 Phosphorylation Sites Overlap
ith Those Observed In Vivo
o verify that the reconstitution of Rad9-dependent
ad53 phosphorylation by Mec1 recapitulates Rad53
hosphorylation after DNA damage, we examined whether
he sites phosphorylated by Mec1 in vitro overlap with
he sites mapped on Rad53 purified from yeast cells.
irst, we tested whether the Rad53D339A, A8 mutant,
hich is not appreciably phosphorylated in vivo (Figure
), can act as an efficient substrate in Mec1 kinase
eactions. As shown in Figure 6A, substitution of
ad53D339A by the Rad53D339A, A8 mutant in Mec1 kinase
ssays (in the presence of Rad9) results in a marked de-
rease in incorporation of radioactivity onto Rad53, sug-
esting that some of the sites mapped in vivo are essen-
ial for Rad53 phosphorylation by Mec1 in vitro.
In parallel to these experiments, Rad53D339A was
hosphorylated by Mec1 in the presence of Rad9 on a
reparative scale (Figure 6B), and Rad53 phosphoryla-
ion sites were then mapped by mass spectrometry, as
escribed above. Satisfyingly, we unambiguously iden-
ified 13 sites, seven of which were also identified in
ivo (Figure 6C and Table S2). Of these seven sites, two
orrespond to S/T-Q sites, three to S/T-ψ sites, and two
o S-S motifs (Table S2). Interestingly, some of the sites
apped in our in vitro kinase reactions were previously
apped on wt Rad53 and not on Rad53D339A (see Table
1 and Figure 2E), perhaps indicating that some sites
ere missed in our analysis of the Rad53D339A sample.
herefore, we conclude that we are, at least partially,
ble to reconstitute the phosphorylation of Rad53 ob-
erved in vivo after DNA damage. Overall, the reconsti-
ution assays described herein support the adaptor
odel for Rad9 function, indicate that Mec1 directly
hosphorylates Rad53 in vitro and in vivo, and suggest
hat Mec1 phosphorylation of Rad53 is essential for its
ubsequent catalytic activation.
iscussion
ad9 was the first checkpoint protein identified in yeast
y the pioneering work of Weinert and Hartwell [33].
s the founding member of the group of checkpoint
ediator proteins, the elucidation of the function of
ad9 may bring new light to the role of checkpoint me-
iators in checkpoint signaling. In this study, we found
hat direct phosphorylation of Rad53 by Mec1 is re-
uired for its catalytic activation. Furthermore, based
n biochemical reconstitution experiments, our results
uggest that an important role of Rad9 in Rad53 activa-
ion is to promote phosphorylation of Rad53 by its up-
tream activator, Mec1. In that sense, the function of
ad9 in Rad53 activation is more akin to classical sig-
aling adaptors. To our knowledge, our data present
he first direct biochemical evidence supporting the
daptor model of checkpoint mediator function. How-
ver, our data do not exclude a mixed model whereby
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1371Figure 5. Rad9 Acts as an Adaptor to Facilitate Rad53 Phosphorylation by Mec1 In Vitro
(A) Rad9 stimulates phosphorylation of Rad53 by Mec1 in vitro. In vitro kinase assays were carried out by using a constant amount of Mec1
and Rad53D339A in the absence or increasing amounts of purified Rad9. The presence of Rad9 was monitored by silver staining, and the
levels of Rad53 were monitored by anti-His tag immunoblotting (bottom panels).
(B) Rad9 does not increase Mec1 intrinsic kinase activity. Protein kinase reactions were carried out as above with the exception that phosphor-
ylation of PHAS-I was also measured in the presence and absence of Rad9. Addition of Rad9 does not significantly increase Mec1 activity
toward PHAS-I.
(C) Quantification of the PHAS-I/Rad53 kinase assays described in (B). Please note that the data for Rad53 phosphorylation +/− Rad9 were
quantitated from the kinase reaction shown in (D) (lane 7 versus 5).
(D) In vitro Mec1 kinase assays using equimolar concentration of Rad53D339A or Rad53D339A, FHA1,2 as substrates were performed in the
presence of [γ-32P]ATP in the presence or absence of Rad9. In one reaction (lane 9), the PIKK inhibitor wortmannin was also included. Proteins
were separated on SDS-PAGE and transferred onto a PVDF membrane, and radioactivity incorporation was measured by phosphorimaging.
The presence of Rad53 was monitored by immunoblotting using anti-His tag antibody (bottom). Please note that the apparent “shift” displayed
by the Rad53D339A, FHA1,2 protein is due to a longer hexahistidine tag.
(E) In vitro Mec1 kinase assay was performed in the presence of Rad53D339A and equimolar concentration of purified Rad9, dephosphorylated
Rad9, or Rad9 subjected to a mock dephosphorylation reaction (see Figures S3B and S3C). The proteins were incubated in the presence of
[γ-32P]ATP, separated by SDS-PAGE, and transferred to PVDF membrane. The presence of radioactivity incorporation was monitored by
phosphorimaging (top), and the presence of Rad53D339A was monitored by immunoblotting using an anti-His antibody (bottom).Rad9 would play two distinct roles during Rad53 acti-
vation: first as a Mec1 adaptor and then as a facilitator
of Rad53 autophosphorylation, perhaps of the activa-
tion segment, by increasing the local concentration of
Rad53 on the Rad9 surface.Mec1 therefore plays two distinct roles in the Rad53
activation cycle (Figure 7A). Firstly, after detection of
DNA damage, Mec1 phosphorylates multiple Rad9 resi-
dues at S/T-Q sites [7]. Rad9 phosphorylation pre-
sumably occurs at regions of DNA damage [34, 35],
Current Biology
1372Figure 6. In Vitro Rad53 Phosphorylation Sites Overlap with Those Observed In Vivo
(A) The Rad53D339A, A8 mutant is not efficiently phosphorylated by Mec1. In vitro Mec1 kinase assays using equimolar concentration
Rad53D339A or Rad53D339A, A8 as substrates were performed in the presence of [γ-32P]ATP. Proteins were separated by SDS-PAGE, transferred
onto a PVDF membrane, and analyzed by phosphorimaging (top) or immunoblotting by using an anti-His tag antibody (bottom). The difference
in size between Rad53D339A or Rad53D339A, A8 is due to an additional 31 amino acids residue between the C-terminal hexahistidine sequence
and the stop codon (see Supplemental Experimental Procedures).
(B) Recombinant Rad53D339A was phosphorylated by Mec1 in the presence of Rad9 on a preparative scale. After termination of the kinase reaction,
proteins were separated by SDS-PAGE and visualized by colloidal Coomassie-staining (left). In a separate reaction, radiolabeled [γ-32P]ATP was
added to monitor phosphorylation by phosphorimaging (right).
(C) Phosphorylated residues identified on Rad53D339A phosphorylated by Mec1. Sites that were also identified in vivo are boxed. The sequence
of these sites can be found in Table S2.and multisite-phosphorylated Rad9 recruits Rad53 to P
IDNA lesions in an FHA-dependent manner [8–11, 35].
Mec1 then acts a second time to phosphorylate Rad9 t
tbound Rad53 on multiple sites. This multisite phos-
phorylation of Rad53 presumably contributes to the re- C
mlief of catalytic autoinhibition, allowing Rad53 to be-
come active. The relief of catalytic autoinhibition by c
cprotein phosphorylation is often used as a catalytic
switching mechanism by protein kinases [36]. After Mec1 t
tphosphorylation, Rad53 autophosphorylates itself on
many residues, including S350 and T354 in the activa- p
dtion segment. We propose that activation segment au-
tophosphorylation completes the Rad53 activation pro- c
tcess, as in most kinases [37]. Active Rad53 is finally
released from Rad9 [18], liberating Rad9 for another [
dround of Rad53 activation or for inactivation by the ac-
tion of protein phosphatases (Figure 7A). The role of d
mautophosphorylation outside the activation segment re-
mains to be ascertained, but it is tempting to speculate a
dthat at least some of these sites promote the release
of Rad53 from Rad9 or promote the phosphorylation- d
tdependent Rad53-Dun1 interaction.IKK-Dependent Activation of Rad53 Orthologs
n both fission yeast and in human cells, the Rad53 or-
hologs (Cds1 and Chk2, respectively) are also subject
o direct phosphorylation by PIKKs. However, Cds1 and
hk2 are phosphorylated by PIKKs on important N-ter-
inal TQ motifs (T11 in S. pombe and T68 in human
ells) in response to DNA damage [38, 39]. In human
ells, T68 phosphorylation of Chk2 by ATM is thought
o promote the formation of Chk2 multimers, which are
hen competent to autoactivate via trans autophos-
horylation [40]. The formation of these multimers is
ependent on the Chk2 FHA domain. However, in the
ase of Rad53, the analogous residues appear rather
o be involved in the interaction with Asf1 and Dun1
20] and not directly in Rad53 activation. In fact, Rad53
oes not appear to form multimers in response to DNA
amage (F.D.S. and D.D., unpublished data). Further-
ore, despite detecting the phosphorylation of the
nalogous T12 and T15 residues in bacterially pro-
uced hyperphosphorylated Rad53, we have failed—
espite multiple attempts—to detect any phosphoryla-
ion on these residues from Rad53 purified from yeast
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1373cells (data not shown). The bacterially produced Rad53
protein is hyperphosphorylated to a great extent, and
many of these autophosphorylation sites seem to be
artifactual, as illustrated by the identification by mass
spectrometry of at least 70 distinct phosphorylation
sites on recombinant Rad53 (F.D.S., F.Y., D.D., and
D.F.H., unpublished data). Therefore, bacterially pro-
duced Rad53 appears to be a poor model to investigate
the phosphoregulation of Rad53. In any case, our data
suggest that phosphorylation of this cluster is not a uni-
versally conserved mechanism for the regulation of
Chk2 orthologs.
Physiologically Relevant Noncanonical
PIKK Phosphorylation
Many members of the PIKK family such as Mec1 (ATR),
Tel1 (ATM), or DNA-PK prefer to phosphorylate S/T-Q
sites [7, 41, 42]. Such substrate selectivity has predic-
tive value, and a number of investigations have taken
advantage of this preference to identify biologically re-
levant PIKK phosphorylation events (e.g., see [7, 13,
43]). In this study, we present evidence that Mec1 can
phosphorylate Rad53 in vivo and in vitro on sites that
do not conform necessarily to the S/T-Q consensus. Of
these, most contain hydrophobic residue following
the phosphoacceptor site (the S/T-ψ motif). Although
uncommon, non-S/T-Q site phosphorylation is also ob-
served for PIKKs other than Mec1. For example, ATM
phosphorylates Brca1 in vitro and in vivo on residue
Ser1542 at a S-G motif [44]. In addition, DNA-PK phos-
phorylates the Ku heterodimer on a number of sites that
do not conform to the Ser/Thr-Gln consensus [29]. Why
S/T-ψ phosphorylation is observed on some substrates
and not on others is puzzling. S/T-ψ may represent
suboptimal PIKKs phosphorylation sites, and theirFigure 7. Models of DNA Damage Check-
point Activation
(A) Model of Rad53 activation. After Mec1/
Ddc2 activation by DNA lesions (1), Mec1
phosphorylates the adaptor molecule Rad9
on multiple S/T-Q motifs (2). Phospho-Rad9,
in turn, recruits Rad53 in an FHA-dependent
manner to DNA lesions (3). We propose that
Rad53 recruitment leads to direct phosphor-
ylation of Rad53 by Mec1 (4). Mec1 phos-
phorylation of Rad53 leads to Rad53 activa-
tion and subsequent autophosphorylation
(5). Hyperphosphorylated Rad53 is then re-
leased from Rad9 (6), freeing Rad9 to per-
form another round of Rad53 activation (7).
(B) We propose that checkpoint mediators
act as PIKK adaptors during the DNA dam-
age response, linking PIKKs to their sub-
strates. The diversity of mediators in meta-
zoans suggests that the spatio-temporal
control of the checkpoint response is regu-
lated by a network of protein-protein interac-
tions controlled by checkpoint mediators.phosphorylation by PIKKs may indicate that additional
conditions must be met before they can be phosphory-
lated. For example, one can speculate that physical
colocalization of PIKKs and substrates may result in
such a phosphorylation event. Colocalization of PIKK
and substrate is clearly expected in the case of Ku and
DNA-PKcs or Brca1 and ATM [45]. The fact that Rad53
requires binding to Rad9 in order to be efficiently phos-
phorylated by Mec1 and that Mec1 and Rad9 colocalize
at sites of DNA damage may support this possibility. If
physical colocalization is required for phosphorylation
of non-S/T-Q sites, these noncanonical phosphoryla-
tion sites on Rad53 may provide a mechanism to en-
sure that Rad53 activation only occurs after the proper
physical assembly of the checkpoint signaling appa-
ratus.
Checkpoint Mediators as PIKK Adaptors
In “classical” signal transduction pathways such as
those operating at the cell surface, signaling adaptors
are usually polypeptides that lack known catalytic do-
mains but possess at least two protein-protein interac-
tion domains, usually of a modular nature [46]. In a
general sense, signaling adaptors function to couple
upstream signaling with downstream events by bridg-
ing at least two distinct proteins. The modular nature of
signaling adaptors enables the use of a relatively small
subset of protein domains and target motifs to con-
struct elaborate signaling networks. In such networks,
adaptors also act as regulatory nodes where signaling
can be regulated via signal-dependent protein-protein
interactions.
Based on the above considerations and on the fol-
lowing observations, we propose that Rad9 acts as a
bona fide signaling adaptor during the DNA damage
Current Biology
1374response: (1) Rad9 physically colocalizes with Mec1 at
sites of DNA damage, suggesting that both proteins
may physically interact [34]; (2) the Rad9-Rad53 in-
teraction is essential for Rad53 activation in vivo [8, 9];
and (3) Rad9 greatly stimulates Rad53 phosphorylation
by Mec1 in vitro (this study). We propose that Rad9
functions to physically bridge Rad53 to Mec1 and that
Rad9 may be able to physically interact with Mec1, at
least transiently. It is tempting to speculate that this
latter interaction may be mediated via the tandem
BRCT domains of Rad9, as the Rad9 BRCT domains
are required for checkpoint signaling in vivo [47]. Inter-
estingly, tandem BRCT domains can act as phospho-
peptide recognition modules [48, 49], but whether the
Rad9 BRCT domains act as bona fide phosphopeptide
recognition modules to bind to Mec1 or any other pro-
tein remains to be determined.
Finally, given the similarities between Rad9 and hu-
man checkpoint mediators containing tandem BRCT
domains, we propose that Brca1, MDC1, and 53BP1
also act as PIKK adaptors during the DNA damage re-
1sponse and that this activity represents a common
function of checkpoint mediators. Interestingly, each
known mammalian checkpoint mediator harbors a
unique protein-interaction module such as the FHA do-
1main (Mdc1), RING finger (Brca1), or the Tudor domain
(53BP1), indicating that they promote either a unique
set of protein-protein interactions or engage an over-
1
lapping set of proteins in response to different up-
stream signals. The requirement for multiple checkpoint
mediators in mammals may reflect the increased com-
1plexity of the mammalian genome or may indicate that
novel layers of regulation were added during metazoan
evolution. By virtue of these properties, we therefore
1propose that checkpoint mediators are PIKK adaptors
that orchestrate the DNA damage response in space
and time. 1
1
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Supplemental Data include Supplemental Results, Supplemental
Experimental Procedures, Supplemental References, three figures,
and three tables and are available with this article online at http:// 1
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